Agent View

Machine representations

Inspect the same governed public record as Markdown, structured data, or a retrieval endpoint.

Canonical entity
alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb
Schema
alpha.governance.entity.public.v1
Last reviewed
2026-09-13T04:46:30.796235+00:00
Verification
source_reported
Ownership
unclaimed

Markdown

https://registry.alpha.ac/companies/lyell-immunopharma-inc.md
Open Markdown

Lyell Immunopharma, Inc.

Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero.

Record

FieldValue
Representationalpha-profile-markdown-v3
ProtocolAlpha Governance Facts Protocol 0.1
Schemaalpha.governance.entity.public.v1
Record versionpublic-1
Canonical entityalpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb
Entity typeCompany
Canonical URLhttps://registry.alpha.ac/companies/lyell-immunopharma-inc
PublicationPUBLISHED
Verificationsource_reported
Verification schemaalpha-verification-states-v1
Ownershipunclaimed
Published claims17
Claims under review1
Evidence records3
Conflicts0
Conflicts in internal review0
Observed2026-09-13T04:46:30.796235+00:00
Last reviewed2026-09-13T04:46:30.796235+00:00

Identity

  • Legal name: Lyell Immunopharma, Inc.
  • Display name: Lyell Immunopharma, Inc.

Leadership

  • Clifford J. Friedman: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Elizabeth Nabel: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Lynn Seely, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Martine Rothblatt, Ph.D., J.D., M.B.A.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Otis Brawley, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Richard Klausner, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • Sumant Ramachandra, M.D., Ph.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • William Rieflin: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:2.
  • David Shook, M.D.: Chief Medical Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.
  • Gary Lee, Ph.D.: Chief Scientific Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.
  • Lynn Seely, M.D.: President, Chief Executive Officer and Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.
  • Mark Meltz: General Counsel and Corporate Secretary. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.
  • Smital Shah: Chief Financial and Business Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.
  • Stephen Hill: Chief Operating Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:3.

Roles

  • PUBLISHED

Governance

  • NOT_ASSERTED

Board committees

  • PUBLISHED

Financials

  • NOT_ASSERTED

Workforce

  • NOT_ASSERTED

Market and index context

  • PUBLISHED

Legal Name

  • Lyell Immunopharma, Inc.. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:1.

Headquarters

  • US. Publication: UNDER_REVIEW. Verification: source_reported. Assertion: source_reported. Evidence: unlinked, under review.

Entity Status

  • Public listing published. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:1.

Published Fact

  • US. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:1.

Coverage states

FieldValue
IdentityPUBLISHED
BusinessPUBLISHED
LeadershipPUBLISHED
Board and committeesPUBLISHED
GovernanceNOT_ASSERTED
FinancialsNOT_ASSERTED
WorkforceNOT_ASSERTED
OwnershipNOT_ASSERTED
RatingsNOT_PUBLISHED
Market and index contextPUBLISHED

Public sources

Rights

FieldValue
public_retrievalallowed
agent_retrievalallowed
redistributionnot_granted
model_trainingnot_granted
commercial_usenot_specified
relationship_pathfindingnot_granted
direct_contactnot_granted

Limitations

  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.

Alternate representations